Curaleaf Challenges Aurora Board Over Acquisition Rejection

The push arrives as Curaleaf attempts to frame its offer as a superior alternative to Aurora’s current standalone strategy. Curaleaf contends that Aurora’s management has failed to deliver results, pointing to roughly C$5 billion in impairments recorded over the past six years. While Aurora leadership has characterized the takeover bid as opportunistic and undervalued, Curaleaf maintains that its offer represents a 45% premium—one of the highest in the Canadian market over the last decade.

Central to Curaleaf’s argument is the claim that Aurora’s leadership has refused to engage in substantive negotiations, citing a lack of discussion regarding price or potential counteroffers. Curaleaf further alleges that Aurora continues to issue shares through its At-the-Market program at prices lower than those implied by the acquisition bid, effectively diluting existing shareholders. By contrasting its own positive operating cash flow against Aurora’s history of negative cash flows, Curaleaf is positioning itself as the more stable, growth-oriented partner for investors looking for long-term recovery in the volatile cannabis sector.